Colleen Buggs-Saxton
Pediatric Endocrinology · Detroit, MINPI 1750337135
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,537 of the $1,758 with a category attached, or 87.4%. It is spread thinly across 19 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $455 and has fallen 67.7% since, to $147 in 2025.
Across 59 payments — averaging $29.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$407
- Medtronic$394
- Sanofi-aventis U.S. LLC$373
- Abbott$97
- Ascendis Pharma Endocrinology Inc$74
- Pfizer$73
- plus $341 from 13 others
Across 22 payments — averaging $4471.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$85K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
- Boehringer Ingelheim France S.a.s.$2K
- Merck$1K
What the payments were for
- Food & beverage$1,53787%
- Education$22113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $407 |
| Medtronic(2 entities) | 10 | $394 |
| Sanofi-aventis U.S. LLC | 5 | $373 |
| Abbott | 5 | $97 |
| Ascendis Pharma Endocrinology Inc | 3 | $74 |
| Pfizer | 4 | $73 |
| AstraZeneca(2 entities) | 2 | $47 |
| Sequel Med Tech, LLC | 2 | $40 |
| BETA Bionics, Inc. | 2 | $37 |
| Merck | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Zealand Pharma US, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $21 |
| Ascensia Diabetes Care US Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$153
- TZIELD$131
- Norditropin$122
How this compares
$1,758 in reported general payments places this provider in the 65th percentile of 27 pediatric endocrinology providers in Michigan.
Other pediatric endocrinology in Detroit
- Kathleen MoltzDetroit$4K
- Doris TahaDetroit$751
- Maha ElhassanDetroit$312
- Amita AdhikariDetroit$178
- Dalia DalleDetroit$154
- James GutaiDetroit$20
- Michael WoodYpsilanti$59K
- Joyce LeeAnn Arbor$9K
- Jacalyn BishopNovi$9K
- Daniel ShumerAnn Arbor$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.